Malignant multiple sclerosis: clinical and demographic prognostic factors

Esclerose múltipla maligna: fatores prognósticos clínicos e demográficos

Fabricio Hampshire-Araújo¹, Anke Bergmann², Regina Maria Papais Alvarenga³,⁴, Cláudia Cristina Ferreira Vasconcelos¹

1Universidade Federal do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil; 2Instituto Nacional de Câncer, Rio de Janeiro RJ, Brasil; 3Hospital Federal da Lagoa, Departamento de Neurologia, Rio de Janeiro RJ, Brasil; 4Hospital Universitário Gaffré e Guinle, Departamento de Neurologia, Rio de Janeiro RJ, Brasil.

Correspondence: Fabrício Hampshire-Araújo; Universidade Federal do Estado do Rio de Janeiro, Departamento de Neurologia; Rua Mariz e Barros, 775; 22290-240 Rio de Janeiro RJ, Brasil; E-mail: fabhampshire@gmail.com

Conflict of interest: There is no conflict of interest to declare.

Received 08 August 2016; Accepted 21 November 2016.

ABSTRACT

Patients with malignant multiple sclerosis (MMS) reach a significant level of disability within a short period of time (Expanded Disability Status Scale score of 6 within five years). The clinical profile and progression of the disease were analyzed in a Brazilian cohort of 293 patients. Twenty-five (8.53%) patients were found to have MMS and were compared with the remaining 268 (91.47%). Women, non-white patients, older age at disease onset, shorter intervals between the first attacks, and more attacks in the first two years of the disease were all more common in the MMS group. These findings could serve as prognostic factors when making therapeutic decisions.

Keywords: multiple sclerosis; disease progression.

METHODS

This observational study included a retrospective analysis of demographic data and clinical data collected from medical records of 293 MS patients according to McDonald et al criteria. The patients had been regularly followed up at the Hospital Federal da Lagoa in Rio de Janeiro, Brazil. Based on the time to reach EDSS 6, patients were classified as MMS up to five years, or non-malignant-MS (NMMS) after five years. The internal review board of the Gafrée and Guinle Teaching Hospital approved the protocol.

Frequencies, percentages, means and standard deviations were calculated for demographic and clinical variables. To analyze progression, Kaplan-Meier curves were constructed based on the time to reach EDSS 3 and 6. Evidences were detected for some variables as potential prognostic factors. This study analyzed a cohort of Brazilian patients to identify cases of MMS and potential prognostic factors indicating more severe progression.
analyzed by the log-rank test. To compare malignant and non-malignant forms, odds ratios and 95% confidence intervals were calculated. The Student’s t-test was used to analyze the time between the first attacks. Statistical significance was defined as p < 0.05.

RESULTS

Twenty-five patients had MMS (8.53%). Most were women (52%) and of African descent (52%), 64% of patients were 30 years old or younger at the disease onset. Relapsing remitting MS (RRMS) was more common than the primary-progressive form (PPMS) in NMMS (93.7% versus 68%; p < 0.001), whereas PPMS was more prevalent in MMS (32% versus 5.2%; p < 0.001). There was a non-significant difference between the groups in the mean time from first symptom until diagnosis (4.2 versus 6.0 years). The median time from first symptom until diagnosis was four years for non-malignant form (0.1 to 29 years) and two years for MMS (0.5 to 25 years). Mean time until treatment with disease-modifying drugs was significantly shorter in MMS (4.0 versus 7.7 years; p = 0.025).

Table shows the comparison of the demographic characteristics and clinical progression between groups. Significant differences were found for sex, ethnicity, recovery after the first attack, number of relapses during the first year, and time between the first two attacks.

Regarding the clinical progression, the risk for progression was 10-fold greater for patients with MMS (OR = 14.5; 95%CI: 4.4–48.1); 35.5% of MMS patients had reached secondary progression versus 3.6% in NMMS (p < 0.001). In MMS, 87% of patients reached EDSS 3 within three years and 44% reached EDSS 6 directly, 44% of patients MMS reached EDSS 6 before 40 years of age versus 7% of NMMS patients (p < 0.001). (This data is not shown in the Table).

The time to reach disability markers was significantly shorter in patients with BRMS classified as MMS compared to those classified as NMMS (EDSS 3: 12 versus 192 months, p < 0.001) (EDSS 6: 36 versus 324 months; p < 0.001). The Figure represents time curves to reach EDSS 3 and 6.

DISCUSSION

The nomenclature and criteria define the more severe progressive forms of MS, although the degree of disability and time to reach disability constitute the principal parameters. In addition to MMS, the term aggressive MS has also been used. The different criteria adopted always include the early disability provoked by frequent attacks and/or progression, and intense inflammatory activity detected by magnetic resonance imaging. The term fulminant MS, although adopted previously, is currently associated with Marburg’s variant in which progression is monophasic with inexorable deterioration and rapid death.

Malignant/aggressive forms occur in 4-14% of cases; and this Brazilian cohort, in which 8.5% of patients developed severe disability within five years, confirmed these data. This percentage includes both RRMS and PPMS; however, if only the former were considered, this rate would fall to 5.8%. In the few studies conducted on malignant/aggressive

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>MMS (25)</th>
<th>NMMS (268)</th>
<th>OR (95%CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12 (48.0)</td>
<td>59 (22.1)</td>
<td>3.27</td>
<td>0.007</td>
</tr>
<tr>
<td>Female</td>
<td>13 (52.0)</td>
<td>209 (77.9)</td>
<td>(1.42–7.54)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-white</td>
<td>13(52.0)</td>
<td>78 (29.1)</td>
<td>2.80</td>
<td>0.020</td>
</tr>
<tr>
<td>White</td>
<td>11(44.0)</td>
<td>185 (69.0)</td>
<td>(1.2–6.5)</td>
<td></td>
</tr>
<tr>
<td>Recovery from the first attack</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>9 (37.5)</td>
<td>11 (5.0)</td>
<td>11.5</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>15 (62.5)</td>
<td>211 (95.0)</td>
<td>(4.1–32.1)</td>
<td></td>
</tr>
<tr>
<td>Number of relapses during 1st year</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 or more relapses</td>
<td>10 (40.0)</td>
<td>39 (14.6)</td>
<td>4.6</td>
<td>0.002</td>
</tr>
<tr>
<td>1 relapse</td>
<td>11 (44.0)</td>
<td>198 (73.9)</td>
<td>(1.8–11.6)</td>
<td></td>
</tr>
<tr>
<td>Time interval between 1st and 2nd attacks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 2 years</td>
<td>18 (81.8)</td>
<td>140 (55.8)</td>
<td>3.6</td>
<td></td>
</tr>
<tr>
<td>&gt;2 years</td>
<td>4 (18.2)</td>
<td>111 (44.2)</td>
<td>(1.2–10.8)</td>
<td>0.013</td>
</tr>
</tbody>
</table>

The differences in n correspond to the absence of information.
forms, most patients had RRMS\textsuperscript{3,4}. Of the MMS cases in the present study, over half had RRMS.

Including PPMS patients may create a bias, since their progression rate is faster, with these patients reaching EDSS 6 within five years. Gholipour et al. included PPMS patients and reported a frequency of MMS of 78.57\%\textsuperscript{3}, while Menon et al. reported 25.57\% of PPMS cases in a group of MMS patients\textsuperscript{4}.

Despite the severity, RRMS patients respond to treatment with immunomodulators and immunosuppressant and immunosuppressive therapy if inflammatory activity is present\textsuperscript{6}. Only RRMS patients are included in the progression curves presented here, and the median times until reaching the markers of moderate and severe disability were one and three years respectively, revealing a short period in which there is a viable therapeutic window. Although no consensus exists on the time and degree of disability required to classify MS as severe, EDSS 6 is used as a cut-off point for the implementation of aggressive treatment\textsuperscript{4}.

In studies on the natural history of MS, clinical factors have been linked to a more severe prognosis\textsuperscript{3,4,8,9,10}. Many of these factors were observed in the patients classified as MMS in this study. There were significantly more patients of African descent, patients in whom motor symptoms were the first manifestation, a shorter time interval between initial attacks, more patients with a residual deficit from the first attack, more patients with more than one attack in the first year, and more cases of progression right from the onset. Conversely, MMS has been described as being more common in men\textsuperscript{3,4}, while in this study more women had MMS. A larger sample population may have achieved different results.

In conclusion, according to the generally accepted concept of MMS, < 10\% of patients in this Brazilian cohort reached severe disability within five years. Identifying demographic and clinical prognostic factors may make early treatment with more effective drugs more feasible.

**References**


EDSS: Expanded Disability Status Scale; RRMS: Relapsing remitting MS.

**Figure.** Kaplan Meier curves of time in months to reach EDSS 3 and 6 for RRMS malignant and no malignant.